비교리스트

 카트 문의
시장보고서
상품코드
1630954

오메가 3 처방약 시장 규모, 점유율, 동향 분석 보고서 : 약제별, 용도별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)

Omega 3 Prescription Drugs Market Size, Share & Trends Analysis Report By Drug (Vascepa, Lovaza), By Application (Cardiovascular), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 80 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

오메가 3 처방약 시장 성장과 동향:

전 세계 오메가 3 처방약 시장 규모는 2030년 18억 달러에 달할 것으로 예상되며, 2030년까지 연평균 4.90%의 성장률을 기록할 것으로 전망됩니다.

이 산업의 성장은 심혈관질환(CVD)의 증가와 식습관의 변화에 기인합니다. 혈중 트리글리세리드 농도의 증가는 심혈관질환의 위험 증가와 관련이 있는 것으로 알려져 있으며, 2021년 유럽심장학회에 따르면 매년 1,790만 명이 CVD로 사망하고 있으며, 이는 전 세계 사망 원인 중 1위입니다. 또한, 오메가 3는 의약품에 대한 응용 가능성이 확대되고 있어, 업계 참여자들의 오메가 3 기반 의약품 출시가 성장을 촉진할 것으로 예상됩니다.

예를 들어, 2020년 미국 FDA는 미국 아마린(Amarin)의 오메가-3 의약품 VASCEPA에 대해 새로운 심혈관 적응증과 라벨 확대를 승인했습니다. 중성지방의 증가는 동맥경화를 일으켜 심장마비나 뇌졸중의 위험을 증가시킵니다. 췌장의 염증인 췌장염도 마찬가지로 극도로 높은 수치에서 발생할 수 있습니다. 트리글리세리드 수치는 당뇨병과 비만의 결과로 상승하며, 이는 널리 퍼져 있는 문제입니다. 미국 성인의 평균 25%는 혈중 알코올 농도가 경계선 이상으로 높습니다. 오메가 3 지방산 약물은 미국 FDA가 승인한 500mg/dl 이상의 트리글리세리드 수치에 대해서만 처방됩니다. 오메가 3 처방약은 COVID-19 팬데믹 기간 동안 큰 시장 움직임을 보였습니다.

이는 CVD 환자 관리에서 중요한 역할을 하기 때문입니다. 예를 들어, 2021년 8월 Woodward Pharma Services LLC는 GlaxoSmithKline으로부터 LOVAZA를 인수했다고 발표했습니다. 이 회사는 소비자와 의료 서비스 제공자를 교육하고 제품 채택을 촉진하는 것을 목표로 하고 있습니다. 또한, 중성지방을 낮추기 위한 여러 연구 개발 연구가 진행되고 있습니다. 중성지방 수치 상승에 대한 17개의 체계적인 무작위 임상시험에서 얻은 결과를 종합적으로 분석한 결과, 처방된 오메가 3 지방산 약물이 중성지방 수치를 20-30% 낮출 수 있는 것으로 나타났습니다. 이에 따라 제품 수요가 높을 것으로 예상됩니다.

오메가 3 처방약 시장 : 분석 개요

  • Lovaza는 예측 기간 동안 완만한 성장 기회가 예상됩니다.
  • 심혈관이 2024년 86.8%의 가장 큰 매출 점유율을 차지하며 시장을 장악했습니다.
  • 소매 약국은 광범위한 접근성과 소비자 편의성으로 인해 2024년 53.6%의 가장 큰 매출 점유율을 차지했습니다.
  • 온라인 약국 분야는 편리하고 접근하기 쉬운 의료 솔루션에 대한 소비자 선호도가 높아짐에 따라 완만한 성장이 예상됩니다.
  • 북미는 2024년 42.9%의 점유율로 세계 오메가 3 처방약 시장을 장악했으며, 예측 기간 동안 큰 폭으로 성장할 것으로 전망됩니다.

목차

제1장 분석 방법·범위

제2장 주요 요약

제3장 오메가 3 처방약 시장 : 변수, 동향, 범위

  • 시장 연관 전망
    • 상부 시장 전망
    • 관련/부수 시장 전망
  • 시장 역학
    • 시장 성장 촉진요인 분석
    • 시장 성장 억제요인 분석
  • 오메가 3 처방약 시장 : 분석 툴
    • 업계 분석 : Porter's Five Forces 분석
    • PESTEL 분석

제4장 오메가 3 처방약 시장 : 약제별 추정·동향 분석

  • 부문별 대시보드
  • 오메가 3 처방약 시장 : 약제별 변동 분석
  • 오메가 3 처방약 시장 : 약제별
  • 시장 규모 예측과 동향 분석(2018-2030년)
  • 바세파
  • 로바자
  • 기타

제5장 오메가 3 처방약 시장 : 용도별 추정·동향 분석

  • 부문별 대시보드
  • 오메가 3 처방약 시장 : 용도별 변동 분석
  • 오메가 3 처방약 시장 전망 : 용도별
  • 시장 규모 예측과 동향 분석(2018-2030년)
  • 심혈관
  • 기타

제6장 오메가 3 처방약 시장 : 유통 채널별 추정·동향 분석

  • 부문별 대시보드
  • 오메가 3 처방약 시장 : 유통 채널별 변동 분석
  • 오메가 3 처방약 시장 전망 : 유통 채널별
  • 시장 규모 예측과 동향 분석(2018-2030년)
  • 병원 약국
  • 소매 약국
  • 온라인 약국

제7장 오메가 3 처방약 시장 : 지역 추정·동향 분석

  • 지역별 대시보드
  • 시장 규모 예측과 동향 분석(2018-2030년)
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 노르웨이
    • 스웨덴
    • 덴마크
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트
    • 쿠웨이트

제8장 경쟁 구도

  • 시장 진출 기업 분류
  • 최근 동향과 영향 분석 : 주요 시장 진출 기업별
  • 기업별 시장 점유율 분석(2024년)
  • 주요 기업 개요
    • Amarin Pharmaceuticals Ireland Limited
    • Woodward Pharma Services LLC
    • Mankind Pharma
    • GLW Pharma GMBH
    • CSPC Pharmaceutical Group Limited
    • Sofgen
    • WILSHIRE PHARMACEUTICALS, INC.
    • Sun Pharmaceutical Industries Ltd.
    • PuraCap Pharmaceutical LLC
    • ChartwellPharma
    • Amneal Pharmaceuticals LLC
KSM 25.02.28

Omega 3 Prescription Drugs Market Growth & Trends:

The global omega 3 prescription drugs market size is expected to reach USD 1.80 billion in 2030 and is expected to expand at a CAGR of 4.90% by 2030. The growth of the industry is attributed to the rising cases of Cardiovascular Diseases (CVDs) and altered dietary practices. An elevated level of triglycerides in the blood is now known to be associated with an increased risk of cardiovascular disease. According to the European Society of Cardiology in 2021, 17.9 million people die from CVDs each year, making it the leading cause of death worldwide. Furthermore, due to the expanding product application potential in medicines, omega 3-based pharmaceutical product launches by industry participants are anticipated to boost its growth.

For instance, in 2020, the U.S. FDA authorized a new cardiovascular indication and label expansion for the omega-3 medication VASCEPA, manufactured by U.S.-based Amarin Corporation. An increase in triglycerides can cause artery narrowing, which raises the risk of heart attack and stroke. Pancreatitis, an inflammation of the pancreas, can result from extremely high levels as well. Triglyceride levels rise as a result of diabetes and obesity, which is a widespread issue. An average of 25% of American adults have high borderline blood alcohol concentrations. The omega-3 fatty acid medications are prescribed only for triglycerides levels above 500 mg/dl as approved by the U.S. FDA. The omega 3 prescription drugs demonstrated a significant market movement during the COVID-19 pandemic.

This is owing to their significant role in the management of CVD patients. For instance, in August 2021, Woodward Pharma Services LLC announced the acquisition of LOVAZA from GlaxoSmithKline. The company further aims to educate consumers and providers to facilitate higher adoption of the product. Moreover, multiple R&D studies are being conducted for lowering triglycerides; combined and analyzed findings from 17 organized and randomized clinical trials on elevated triglyceride levels, suggest that prescription omega-3 fatty acid medication can reduce levels by 20-30%. This is expected to create high product demand.

Omega 3 Prescription Drugs Market Report Highlights:

  • Lovaza is projected to experience moderate growth opportunities during the forecast period.
  • Cardiovascular dominated the market and accounted for the largest revenue share of 86.8% in 2024
  • Retail pharmacy dominated the market and accounted for the largest revenue share of 53.6% in 2024 due to its wide accessibility and consumer convenience
  • The online pharmacy segment is expected to witness moderate growth due to the increasing consumer preference for convenient and accessible healthcare solutions
  • North America dominated the global omega 3 prescription drugs market with a share of 42.9% in 2024 and is anticipated to grow significantly over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug
    • 1.2.2. Application
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Omega 3 Prescription Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Prevalence of Cardiovascular Diseases
      • 3.2.1.2. Growing Awareness of Omega-3 Health Benefits
      • 3.2.1.3. Advancements in Pharmaceutical Formulations
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost of Prescription Omega-3 Drugs
      • 3.2.2.2. Regulatory and Reimbursement Challenges
  • 3.3. Omega 3 Prescription Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Omega 3 Prescription Drugs Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Omega 3 Prescription Drugs Market: Drug Movement Analysis
  • 4.3. Omega 3 Prescription Drugs Market by Drug (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Vascepa
    • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Lovaza
    • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Omega 3 Prescription Drugs Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Omega 3 Prescription Drugs Market: Application Movement Analysis
  • 5.3. Omega 3 Prescription Drugs Market by Application Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Cardiovascular
    • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Omega 3 Prescription Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Omega 3 Prescription Drugs Market: Distribution Channel Movement Analysis
  • 6.3. Omega 3 Prescription Drugs Market by Distribution Channel Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospital Pharmacy
    • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Retail Pharmacy
    • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Online Pharmacy
    • 6.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Omega 3 Prescription Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Company Market Share Analysis, 2024
  • 8.4. Key Company Profiles
    • 8.4.1. Amarin Pharmaceuticals Ireland Limited
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Woodward Pharma Services LLC
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Mankind Pharma
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. GLW Pharma GMBH
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. CSPC Pharmaceutical Group Limited
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Sofgen
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. WILSHIRE PHARMACEUTICALS, INC.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Sun Pharmaceutical Industries Ltd.
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. PuraCap Pharmaceutical LLC
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. ChartwellPharma
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Amneal Pharmaceuticals LLC
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제